Track topics on Twitter Track topics that are important to you
In its second quarter financial reports, Valeant strove to strike a positive note. It revealed that it had paid down $4.8 billion on its mountain of debt since the first quarter of 2016 and CEO, Joseph Papa, said that the company would focus on launching new products, instead of selling parts of the business, to further reduce this.
This message was marred slightly by the previous day’s news, which revealed that the aim of bringing new products to market had been missed on its eye drug that had been issued a second CRL on manufacturing issues.
Original Article: Valeant focused on bringing new products to market, receives CRLNEXT ARTICLE
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...